A Diabetes Guideline Built for a Later Stage of Her Own Disease
The guideline's insulin-first logic is built around CFRD as it usually looks by the time it's caught. Her disease, caught early and mild, doesn't quite match the population the recommendation was written for — and the disagreement is about how much that should matter.
Josephine V., a 24-year-old woman, has cystic fibrosis diagnosed in infancy and works as a graphic designer from home, a career she chose partly because it lets her build her workday around her airway clearance routine and nebulizer treatments without having to explain them to anyone. Her annual CF clinic screening oral glucose tolerance test this year showed a normal fasting glucose but a two-hour value of 224 mg/dL, meeting criteria for cystic fibrosis-related diabetes — her first CFRD diagnosis after years of normal or borderline screening results. Her lung function has been stable, with no recent exacerbations, and her weight has held steady over the past year, a genuinely reassuring sign in a disease where nutritional status and pulmonary trajectory are closely linked.
CFRD is mechanistically distinct from typical type 2 diabetes in a way that shapes the whole treatment conversation: it arises primarily from progressive damage to the pancreas's insulin-producing tissue as part of the same exocrine process that affects her lungs and digestion, not principally from insulin resistance. That distinction is why the Moran-led Cystic Fibrosis Foundation/ADA guidance recommends insulin as first-line therapy for CFRD generally, reasoning that a fundamentally insulin-deficient process is best matched with insulin itself, and that insulin's anabolic properties actively support the weight and nutritional status that matter so much to her lung health. Her own presentation, though, is on the milder end of what that guidance was built around — postprandial elevation only, normal fasting glucose — and she's told the team directly she'd like to understand whether a less intensive option is reasonable before starting insulin.
A guideline built for a different point in the same disease
I'd start insulin per current CFRD-specific guidance, regardless of how mild her presentation looks today. CFRD's underlying mechanism is genuine insulin deficiency from progressive pancreatic damage, not primarily insulin resistance — a fundamentally different process than typical type 2 diabetes, which is exactly why the guideline recommends insulin as first-line rather than the oral agents used elsewhere. Insulin's anabolic effect also directly supports her nutritional status, which matters enormously for her lung trajectory.
I'd consider a bounded trial of a non-insulin option first, given how mild her actual pattern is — postprandial-only elevation, completely normal fasting glucose, stable weight and lung function. The guideline's insulin-first reasoning was built around a broader CFRD population that typically includes more advanced, fasting-hyperglycemic disease. She's expressed real, specific reluctance, and her presentation genuinely sits closer to the mild end of that spectrum than the guideline's typical case.
I'm not arguing against insulin ever being right for her — her CFRD will likely progress, and I'd expect her to need it eventually. I'm arguing that "eventually" isn't necessarily "today," given how mild this specific presentation actually is.
Whichever baseline regimen you two land on, I want an explicit, written plan for rapid insulin initiation during her next pulmonary exacerbation, regardless of what she's on today. Infection and the corticosteroids often used to treat exacerbations reliably produce acute insulin resistance in CF patients — that's not a hypothetical risk, it's close to a universal feature of this disease course.
A stable baseline oral regimen, if that's what's chosen, simply won't cover her during that acute window. This needs to be a concrete protocol in her chart, not a general awareness that "diabetes control gets harder when she's sick."
Mealtime-only rapid-acting insulin started, matched to her postprandial-only pattern, with a written exacerbation escalation protocol placed in her chart and reviewed with her directly. Josephine said she felt more comfortable starting insulin once she understood it was being scaled to match her actual glucose pattern rather than a full standard regimen regardless of severity.
Not agreed: whether her next OGTT reassessment should be at six months or a full year. The endocrinologist wanted six months given CFRD's known tendency to progress; the pulmonologist felt annual reassessment, aligned with her regular CF clinic visits, was sufficient given her currently mild and stable presentation. Left for the CF care team to finalize.